Don't take migraines lying down, Allergan's new Botox ad urges


Most people think "wrinkles" when they hear Botox. But maker Allergan wants consumers to think "chronic migraines," too.

A new TV ad debuted this week features women who spurn conventional advice for migraines declaring, “I don’t want to lie down"--the upshot being that they don’t have to take chronic migraines lying down.

Botox has been approved as a migraine treatment since 2010, and a more traditional campaign that began in 2013 is also still running. Spending on that campaign with two different spots has totaled about $57 million in those three years, according to data from realtime TV ad tracker


[Infographic] Machine Learning, Statistics and Optimizing Outcomes

In this infographic, Medidata outlines the potential of fusing machine learning and statistics algorithms together to more efficiently analyze clinical trial data output and ultimately revolutionize clinical research.

As a result, both the therapy's aesthetic and therapeutic indications are growing revenues, according to Allergan's latest financials. Sales of the product topped $638 million in Q1 of this year, driven by "continued strong performance" in each of those two categories.

Competitors in the migraine treatment category are diverse, though, and they range from beta blockers and certain antidepressants to anti-seizure and OTC anti-inflammatories. And more next-generation treatments are on the way, too, with fierce competition in the CGRP inhibitor space. Alder Therapeutics appears to have the lead right now in Phase III, but Teva, Eli Lilly and Amgen are all also moving quickly forward with their own late-stage efforts.

- see the new TV spot

Related Articles:
Alder rockets up as promising migraine data heats up a frenzied race for CGRP drug approval
Teva enlists House M.D. actress to amp up migraine awareness
Actavis CEO: Pharma believer and Botox user, yes. The Borg? No
Avanir's intranasal migraine med gets past FDA on second try


Suggested Articles

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.

Acadia’s Nuplazid is under the gun after prosecutors launched a marketing probe in March. Now the drug has to cope with a trial flop in schizophrenia.

Chinese CDMO GenScript Biotech opened a new biologics clinical supply manufacturing facility even as it is working on a commercial supply facility.